Shang Weijing, Wang Yaping, Yuan Jie, Guo Zirui, Liu Jue, Liu Min
School of Public Health, Peking University, Beijing 100191, China.
Vaccines (Basel). 2022 Oct 12;10(10):1702. doi: 10.3390/vaccines10101702.
Currently, reported COVID-19 deaths are inadequate to assess the impact of the pandemic on global excess mortality. All-cause excess mortality is a WHO-recommended index for assessing the death burden of COVID-19. However, the global excess mortality assessed by this index remains unclear. We aimed to assess the global excess mortality during the COVID-19 pandemic.
We searched PubMed, EMBASE, and Web of Science for studies published in English between 1 January 2020, and 21 May 2022. Cross-sectional and cohort studies that reported data about excess mortality during the pandemic were included. Two researchers independently searched the published studies, extracted data, and assessed quality. The Mantel-Haenszel random-effects method was adopted to estimate pooled risk difference (RD) and their 95% confidence intervals (CIs).
A total of 79 countries from twenty studies were included. During the COVID-19 pandemic, of 2,228,109,318 individuals, 17,974,051 all-cause deaths were reported, and 15,498,145 deaths were expected. The pooled global excess mortality was 104.84 (95% CI 85.56-124.13) per 100,000. South America had the highest pooled excess mortality [134.02 (95% CI: 68.24-199.80) per 100,000], while Oceania had the lowest [-32.15 (95% CI: -60.53--3.77) per 100,000]. Developing countries had higher excess mortality [135.80 (95% CI: 107.83-163.76) per 100,000] than developed countries [68.08 (95% CI: 42.61-93.55) per 100,000]. Lower middle-income countries [133.45 (95% CI: 75.10-191.81) per 100,000] and upper-middle-income countries [149.88 (110.35-189.38) per 100,000] had higher excess mortality than high-income countries [75.54 (95% CI: 53.44-97.64) per 100,000]. Males had higher excess mortality [130.10 (95% CI: 94.15-166.05) per 100,000] than females [102.16 (95% CI: 85.76-118.56) per 100,000]. The population aged ≥ 60 years had the highest excess mortality [781.74 (95% CI: 626.24-937.24) per 100,000].
The pooled global excess mortality was 104.84 deaths per 100,000, and the number of reported all-cause deaths was higher than expected deaths during the global COVID-19 pandemic. In South America, developing and middle-income countries, male populations, and individuals aged ≥ 60 years had a heavier excess mortality burden.
目前,报告的新冠病毒疾病(COVID-19)死亡人数不足以评估该大流行对全球超额死亡率的影响。全因超额死亡率是世界卫生组织推荐的用于评估COVID-19死亡负担的指标。然而,用该指标评估的全球超额死亡率仍不明确。我们旨在评估COVID-19大流行期间的全球超额死亡率。
我们在PubMed、EMBASE和科学网中检索了2020年1月1日至2022年5月21日期间以英文发表的研究。纳入报告了大流行期间超额死亡率数据的横断面研究和队列研究。两名研究人员独立检索已发表的研究、提取数据并评估质量。采用Mantel-Haenszel随机效应方法估计合并风险差(RD)及其95%置信区间(CI)。
共纳入来自20项研究的79个国家。在COVID-19大流行期间,在2228109318名个体中,报告了17974051例全因死亡,预期死亡15498145例。全球合并超额死亡率为每10万人104.84例(95%CI 85.56 - 124.13)。南美洲的合并超额死亡率最高[每10万人134.02例(95%CI:68.24 - 199.80)],而大洋洲最低[每10万人 - 32.15例(95%CI: - 60.53 - - 3.77)]。发展中国家的超额死亡率[每10万人135.80例(95%CI:107.83 - 163.76)]高于发达国家[每10万人68.0捌例(95%CI:42.61 - 93.55)]。中低收入国家[每10万人133.45例(95%CI:75.10 - 191.81)]和中高收入国家[每10万人149.88例(110.35 - 189.38)]的超额死亡率高于高收入国家[每10万人75.54例(95%CI:53.44 - 97.64)]。男性的超额死亡率[每10万人130.10例(95%CI:94.15 - 166.05)]高于女性[每10万人102.16例(95%CI:85.76 - 118.56)]。年龄≥60岁的人群超额死亡率最高[每10万人781.74例(95%CI:626.24 - 937.24)]。
全球合并超额死亡率为每10万人104.84例死亡,在全球COVID-19大流行期间,报告的全因死亡人数高于预期死亡人数。在南美洲、发展中国家和中等收入国家、男性人群以及年龄≥60岁的个体中,超额死亡负担更重。